Patents by Inventor Holger Summer
Holger Summer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230151442Abstract: A lysis buffer comprising one non-ionic surfactant is provided which can be used as a one-step reagent of the preparation, storage, amplification, and/or detection of nucleic acids. Various embodiments of the lysis buffer of the invention comprise other substances that are compatible or useful in lysing cells, storing nucleic acids, amplifying nucleic acids, purifying nucleic acids, detecting nucleic acids, and/or other procedures for analysis of nucleic acids. Methods and kits based on the lysis buffer are also provided, including those for rapid lysis of cells and direct use of the resulting cell lysates in RT-PCR.Type: ApplicationFiled: April 1, 2021Publication date: May 18, 2023Applicant: Bayer AktiengesellschaftInventors: Stefan GOLZ, Holger SUMMER, Silke AIGNER, Heidrun ELLINGER-ZIEGELBAUER, Kirsten LEINEWEBER, Thomas MÜLLER
-
Patent number: 8088584Abstract: The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.Type: GrantFiled: October 2, 2007Date of Patent: January 3, 2012Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht-Küpper, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'Urso, Michael Seewald, Hendrik Milting
-
Publication number: 20110111394Abstract: The invention provides CTGF which is associated with the cardiovascular diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases and hematological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CTGF as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: October 4, 2007Publication date: May 12, 2011Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht-Küpper, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'Urso, Michael Seewald, Hendrik Milting
-
Publication number: 20100104501Abstract: The invention provides PRSS23, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSS23 as well as pharmaceutical compositions comprising such compounds. The invention also provides PRSS23 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.Type: ApplicationFiled: October 2, 2007Publication date: April 29, 2010Inventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'urso, Michael Seewald, Hendrik Milting
-
Publication number: 20100081136Abstract: The invention provides CRTAC, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CRTAC as well as pharmaceutical compositions comprising such compounds. The invention also provides CRTAC as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.Type: ApplicationFiled: October 2, 2007Publication date: April 1, 2010Inventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Bruggemeier, Barbara Albrecht-Kupper, Martina Klein
-
Publication number: 20100028264Abstract: The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.Type: ApplicationFiled: October 2, 2007Publication date: February 4, 2010Inventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht-Küpper, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'Urso, Michael Seewald, Hendrik Milting
-
Patent number: 7465548Abstract: The invention provides a human HM74a which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroenterological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of HM74a as well as pharmaceutical compositions comprising such compounds.Type: GrantFiled: February 5, 2004Date of Patent: December 16, 2008Assignee: Bayer Healthcare AGInventors: Stefan Golz, Ulf Brüggemeier, Holger Summer
-
Publication number: 20080050315Abstract: The invention provides a human PRKG1 which is associated with cardiovascular diseases, respiratory diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hemato-logical diseases, muscle-skeleton-diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, respiratory diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, muscle-skeleton-diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRKG1 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: March 10, 2005Publication date: February 28, 2008Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer
-
Publication number: 20080038247Abstract: The invention provides a human GPR39 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR39 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: April 22, 2004Publication date: February 14, 2008Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Bruggemeier, Holger Summer, Ralf Thiele
-
Publication number: 20070298028Abstract: The invention provides a human KLK3 which is associated with the endocrine system and hormone disorders, cardiovascular disorders, metabolic diseases, cancer disorders, neurological disorders, urological disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of endocrine system and hormone disorders, cardiovascular disorders, metabolic diseases, cancer disorders, neurological disorders, urological disorders and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK3 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: February 4, 2005Publication date: December 27, 2007Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer
-
Publication number: 20070269807Abstract: The invention provides a human PRSC1 which is associated with the cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSC1 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: January 22, 2005Publication date: November 22, 2007Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer, Ralf Thiele
-
Publication number: 20070269421Abstract: The invention provides a human PGCP which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urologial diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urologial diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PGCP as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: January 22, 2005Publication date: November 22, 2007Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer
-
Publication number: 20070258973Abstract: The invention provides a human TPP2 which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of TPP2 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: January 19, 2005Publication date: November 8, 2007Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer
-
Publication number: 20070253949Abstract: The invention provides a human KLKB1 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, inflammatory diseases, cancer disorders, muscle-skeleton disorders, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, inflammatory diseases, cancer disorders, muscle-skeleton disorders, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLKB1 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: January 22, 2005Publication date: November 1, 2007Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer
-
Publication number: 20070218047Abstract: The invention provides a human KLK2 which is associated with the hematological disorders, cancer, cardiovascular diseases, inflammatory diseases, neurological disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological disorders, cancer, cardiovascular diseases, inflammatory diseases, neurological disorders, reproduction disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK2 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: January 15, 2005Publication date: September 20, 2007Inventors: Stefan Golz, Ulf Bruggemeter, Andreas Geerts, Holger Summer
-
Publication number: 20070148175Abstract: The invention provides a human KLK12 which is associated with the gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK12 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: January 15, 2005Publication date: June 28, 2007Applicant: Bayer Healthcare agInventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer
-
Publication number: 20070105104Abstract: The invention provides a human LTB4 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of LTB4 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: April 24, 2004Publication date: May 10, 2007Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Bruggemeier, Holger Summer
-
Publication number: 20070071753Abstract: The invention provides a human GPR85 which is associated with the cardiovascular disorders, hematological disorders, inflammatory diseases, metabolic diseases, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, hematological disorders, inflammatory diseases, metabolic diseases, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR85 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: October 19, 2004Publication date: March 29, 2007Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer
-
Publication number: 20070053911Abstract: The invention provides a human PAR2 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, neurological disorders, urological disorders, hematological diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, neurological disorders, urological disorders, hematological diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PAR2 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: February 26, 2004Publication date: March 8, 2007Applicant: Bayer Healthcare AGInventors: Stefan Golz, Ulf Bruggemeier, Holger Summer
-
Publication number: 20060263359Abstract: The invention provides a human DRD4 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of DRD4 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: March 6, 2004Publication date: November 23, 2006Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Bruggemeier, Holger Summer